Sangamo Therapeutics Inc. (SGMO)
NASDAQ: SGMO
· Real-Time Price · USD
0.47
-0.02 (-4.95%)
At close: May 23, 2025, 3:59 PM
0.48
0.93%
After-hours: May 23, 2025, 05:44 PM EDT
Sangamo Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|
| License Revenue | 48.68M | 132.16M | 37.03M |
| License Revenue Growth | -63.17% | +256.89% | n/a |
| Service Revenue | 1.32M | 2.68M | n/a |
| Service Revenue Growth | -50.78% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 10.06M | 9.87M | 11.05M | 12.04M | 8.74M | 10.22M | 13.92M | 16.01M | 18.14M | 16.44M | 16.24M | 15.09M | 14.91M | 16.08M | 14.5M | 16.49M | 16.15M | 16.87M | 16.18M | 17.93M | 16.12M | 15.05M | 14.92M | 14.6M | 17.12M | 14.36M | 10.99M | 11.3M | 10.09M | 7.47M | 6.42M | 6.04M | 7.28M | 4.86M | 5.02M | 11.09M | 5.36M | 4.89M | 4.56M | 5.02M | 4.73M |
| Selling, General, and Administrative Revenue Growth | +1.96% | -10.71% | -8.27% | +37.80% | -14.45% | -26.59% | -13.09% | -11.70% | +10.30% | +1.26% | +7.59% | +1.24% | -7.31% | +10.92% | -12.04% | +2.09% | -4.30% | +4.31% | -9.76% | +11.22% | +7.08% | +0.90% | +2.20% | -14.73% | +19.25% | +30.58% | -2.73% | +12.04% | +35.11% | +16.26% | +6.38% | -17.02% | +49.63% | -3.17% | -54.72% | +107.02% | +9.59% | +7.19% | -9.11% | +6.02% | n/a |
| Research and Development Revenue | 26.01M | 23.68M | 27.73M | 24.22M | 34.59M | 51.21M | 57.09M | 63.05M | 63.22M | 66.18M | 65.12M | 60.02M | 58.58M | 51.8M | 62.5M | 60.09M | 56.43M | 52.36M | 45.29M | 41.52M | 41.48M | 38.33M | 36.29M | 36.45M | 34.85M | 33.25M | 28.81M | 29.25M | 23.55M | 19.38M | 18.43M | 14.98M | 12.94M | 13.89M | 17.01M | 19.45M | 15.27M | 19.91M | 16.69M | 15.62M | 14.98M |
| Research and Development Revenue Growth | +9.85% | -14.63% | +14.49% | -29.97% | -32.45% | -10.30% | -9.45% | -0.27% | -4.48% | +1.63% | +8.49% | +2.45% | +13.09% | -17.12% | +4.01% | +6.47% | +7.78% | +15.61% | +9.06% | +0.11% | +8.22% | +5.62% | -0.46% | +4.61% | +4.80% | +15.43% | -1.52% | +24.24% | +21.52% | +5.17% | +22.96% | +15.78% | -6.83% | -18.33% | -12.57% | +27.43% | -23.31% | +19.24% | +6.89% | +4.26% | n/a |